These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 15535425)
1. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance. Patsouris D; Müller M; Kersten S Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425 [TBL] [Abstract][Full Text] [Related]
2. Selective PPAR agonists for the treatment of type 2 diabetes. Nehlin JO; Mogensen JP; Petterson I; Jeppesen L; Fleckner J; Wulff EM; Sauerberg P Ann N Y Acad Sci; 2006 May; 1067():448-53. PubMed ID: 16804025 [TBL] [Abstract][Full Text] [Related]
3. PPAR ligands: are they potential agents for cardiovascular disorders? Balakumar P; Rose M; Singh M Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434 [TBL] [Abstract][Full Text] [Related]
7. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Gross B; Staels B Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742 [TBL] [Abstract][Full Text] [Related]
8. Strategies for the development of new PPAR agonists in diabetes. Cavender MA; Nicholls SJ; Lincoff AM Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419 [TBL] [Abstract][Full Text] [Related]
9. PPAR agonists and the metabolic syndrome. Staels B Therapie; 2007; 62(4):319-26. PubMed ID: 17983557 [TBL] [Abstract][Full Text] [Related]
11. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Fogo AB Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479 [TBL] [Abstract][Full Text] [Related]
12. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592 [TBL] [Abstract][Full Text] [Related]
13. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. Zieleniak A; Wójcik M; Woźniak LA Arch Immunol Ther Exp (Warsz); 2008; 56(5):331-45. PubMed ID: 18836859 [TBL] [Abstract][Full Text] [Related]
14. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499 [TBL] [Abstract][Full Text] [Related]
15. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus. Rosenson RS Am J Cardiol; 2007 Feb; 99(4A):96B-104B. PubMed ID: 17307062 [TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Giaginis C; Tsantili-Kakoulidou A; Theocharis S Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292 [TBL] [Abstract][Full Text] [Related]
18. The role of PPARs in the microvascular dysfunction in diabetes. Vinik A; Parson H; Ullal J Vascul Pharmacol; 2006 Jul; 45(1):54-64. PubMed ID: 16784897 [TBL] [Abstract][Full Text] [Related]
19. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists]. Heinzl S Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882 [No Abstract] [Full Text] [Related]
20. The metabolic syndrome: relationship between insulin sensitivity and the role of peroxisome proliferator-activated receptors (PPARs) in saccharide and lipid metabolism. Yahia RB; Lichnovská R; Brychta T Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):237-41. PubMed ID: 16601762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]